Clinical Trials Directory

Trials / Unknown

UnknownNCT06266858

Multimodality Imaging Assessment of the Severity of Mitral Regurgitation

A Single-Center, Open-Label Study to Assess the Severity of Mitral Regurgitation With Multimodality Imaging

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To investigate to assess the severity of mitral regurgitation by multimodality imaging.

Detailed description

In the single-center and open-label study, the researcher will compare the changes of ultrasonic cardiography (UCG) parameters when patients in fasting, anaesthesia and rehydration firstly. The aims are to clarify the effect of fasting and anaesthesia on the assessment of mitral regurgitation (MR) severity and the corrective effect of intravenous rehydration. The researcher then will investigate the correlation and consistency of multimodality imaging in assessing the severity of mitral regurgitation. The aim is to acquire more accurate, objective and reproducible parameters, to provide new solution for the precise assessment of MR severity and to guide the selection of clinical treatment and timing.

Conditions

Interventions

TypeNameDescription
OTHERrehydrationThe fasting patients in anaesthetised receive saline rehydration to maintain central venous pressure of 6-8 cmH2O when undergoing UCG.
DIAGNOSTIC_TESTUCGUCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.
DIAGNOSTIC_TESTCMRCMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
OTHERfastingAt the beginning of the study, the patients need to fast when receive UCG.

Timeline

Start date
2022-12-01
Primary completion
2024-06-30
Completion
2024-06-30
First posted
2024-02-20
Last updated
2024-02-20

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06266858. Inclusion in this directory is not an endorsement.